Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial

Cancer

Volumn 118, Issue 19, 2012, Pages 4777-4784

  Ross, Robert W ^a   Galsky, Matthew D ^b   Febbo, Phil ^c   Barry, Marc ^d   Richie, Jerome P ^e   Xie, Wanling ^a   Fennessy, Fiona M ^a   Bhatt, Rupal S ^f   Hayes, Julia ^a   Choueiri, Toni K ^a   Tempany, Clare M ^a   Kantoff, Philip W ^a   Taplin, Mary E ^a   Oh, William K ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

bevacizumab; docetaxel; high risk localized; neoadjuvant; prostate cancer

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANAMNESIS; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BLEEDING; BLURRED VISION; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGITAL RECTAL EXAMINATION; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPIPHORA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GLEASON SCORE; HEADACHE; HICCUP; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; INSOMNIA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATELLA FRACTURE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RHINITIS; SIDE EFFECT; THROMBOEMBOLISM; TUMOR VOLUME; VOCAL CORD DISORDER;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863103342     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27416     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH,. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003; 21: 2163-2172.
3. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351: 125-135.
4. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
5. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
8. Aus G, Abrahamsson PA, Ahlgren G, et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol. 1998; 159: 2013-2016; discussion 2016-2017.
9. Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Oosterhof GO,. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment. Eur Urol. 1994; 26 (suppl 1): 4.
10. Goldenberg SL, Klotz LH, Srigley J, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996; 156: 873-877.
11. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A,. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995; 154: 424-428.
12. Witjes WP, Schulman CC, Debruyne FM,. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology. 1997; 49: 65-69.
13. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME,. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008; 180: 565-570; discussion 570.
14. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004; 63: 1138-1142.
15. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005; 11: 5233-5240.
16. Eastham JA, Kelly WK, Grossfeld GD, Small EJ,. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003; 62 (suppl 1): 55-62.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
19. Ning YM, Figg WD, Dahut WL,. Reversal of docetaxel resistance with bevacizumab and thalidomide. Clin Genitourin Cancer. 2009; 7: E37-E38.
20. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 2070-2076.
21. Picus J, Halabi S, Kelly WK, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011; 117: 526-533.
22. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract]. ASCO Meeting Abstracts. 2010; 28: LBA4511.
23. McDougall SR, Anderson AR, Chaplain MA,. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol. 2006; 241: 564-589.
24. Morris MJ, Basch EM, Wilding G, et al. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009; 7: 51-57.
25. Garzotto M, Higano CS, O'Brien C, et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer. 2010; 116: 1699-1708.
26. Fizazi K, Lesaunier F, Delva R, et al. Docetaxel-estramustine in high-risk localized prostate cancer: first results of the French Genitourinary Tumor Group phase III trial (GETUG 12) [abstract]. ASCO Meeting Abstracts. 2011; 29: 4513.
27. Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P,. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol. 2011; 29: 1-4.
28. Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005; 11: 4905-4911.
29. Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res. 2006; 12: 169-174.